Of note, this drug is representative of the therapeutic class of experimental mGluR5 NAMs recently under investigation in phase II/III clinical trials for neurological diseases other than ALS [125,126,127,128,129], with promising therapeutic and toxicological profiles [127,130,131]. This evidence concerns the gene GRM5 and nervous system disorder.